Simplex Trading’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $309K | Sell |
4,300
-5,700
| -57% | -$325K | ﹤0.01% | 3795 |
|
|
2025
Q4 | $423K | Sell |
10,000
-90,600
| -90% | -$5.07M | ﹤0.01% | 3468 |
|
|
2025
Q3 | $5.72M | Sell |
100,600
-107,100
| -52% | -$3.54M | ﹤0.01% | 1346 |
|
|
2025
Q2 | $5.37M | Buy |
207,700
+202,087
| +3,600% | +$2.27M | ﹤0.01% | 1288 |
|
|
2025
Q1 | $57K | Buy |
+5,613
| New | +$73.3K | ﹤0.01% | 5632 |
|
|
2024
Q4 | – | Sell |
-260
| Closed | -$5K | – | 9260 |
|
|
2024
Q3 | $5K | Sell |
260
-147
| -36% | -$2.8K | ﹤0.01% | 7632 |
|
|
2024
Q2 | $7K | Buy |
407
+74
| +22% | +$1.56K | ﹤0.01% | 7683 |
|
|
2024
Q1 | $4K | Buy |
+333
| New | +$3.49K | ﹤0.01% | 8142 |
|
|
2023
Q4 | – | Sell |
-987
| Closed | -$8K | – | 9476 |
|
|
2023
Q3 | $8K | Buy |
987
+60
| +6% | +$578 | ﹤0.01% | 7339 |
|
|
2023
Q2 | $7K | Buy |
+927
| New | +$9.88K | ﹤0.01% | 7697 |
|
|
2023
Q1 | – | Sell |
-333
| Closed | -$11K | – | 9769 |
|
|
2022
Q4 | $11K | Sell |
333
-467
| -58% | -$22.6K | ﹤0.01% | 7461 |
|
|
2022
Q3 | $38K | Sell |
800
-1,333
| -62% | -$79.3K | ﹤0.01% | 6795 |
|
|
2022
Q2 | $121K | Sell |
2,133
-48,180
| -96% | -$3.04M | ﹤0.01% | 5299 |
|
|
2022
Q1 | $4.07M | Buy |
50,313
+48,386
| +2,511% | +$7.16M | ﹤0.01% | 1424 |
|
|
2021
Q4 | $390K | Buy |
1,927
+774
| +67% | +$168K | ﹤0.01% | 4166 |
|
|
2021
Q3 | $303K | Hold |
1,153
| – | – | ﹤0.01% | 4894 |
|
|
2021
Q2 | $296K | Buy |
1,153
+1,145
| +14,313% | +$317K | ﹤0.01% | 5010 |
|
|
2021
Q1 | $246K | Sell |
8
-27
| -77% | -$8.4K | ﹤0.01% | 4429 |
|
|
2020
Q4 | $901K | Sell |
35
-11
| -24% | -$2.84K | ﹤0.01% | 2702 |
|
|
2020
Q3 | $1.16M | Sell |
46
-1
| -2% | -$315 | ﹤0.01% | 2060 |
|
|
2020
Q2 | $1.65M | Sell |
47
-3
| -6% | -$936 | ﹤0.01% | 1672 |
|
|
2020
Q1 | $1.35M | Sell |
50
-23
| -32% | -$7.11K | ﹤0.01% | 1614 |
|
|
2019
Q4 | $2.35M | Sell |
73
-25
| -26% | -$7.25K | 0.01% | 1337 |
|
|
2019
Q3 | $2.67M | Buy |
98
+53
| +118% | +$19.4K | 0.01% | 1102 |
|
|
2019
Q2 | $2.41M | Buy |
45
+9
| +25% | +$4.51K | 0.01% | 1169 |
|
|
2019
Q1 | $1.83M | Buy |
36
+18
| +100% | +$10.7K | 0.01% | 1439 |
|
|
2018
Q4 | $887K | Sell |
18
-26
| -59% | -$15.7K | ﹤0.01% | 1724 |
|
|
2018
Q3 | $4.07M | Sell |
44
-3
| -6% | -$2.56K | 0.01% | 742 |
|
|
2018
Q2 | $3.47M | Buy |
47
+40
| +571% | +$46.1K | 0.01% | 763 |
|
|
2018
Q1 | $51K | Sell |
7
-27
| -79% | -$34.8K | ﹤0.01% | 2419 |
|
|
2017
Q4 | $40K | Buy |
34
+23
| +209% | +$13.6K | ﹤0.01% | 2656 |
|
|
2017
Q3 | $9K | Sell |
11
-17
| -61% | -$5.32K | ﹤0.01% | 3876 |
|
|
2017
Q2 | $16K | Sell |
28
-26
| -48% | -$7.51K | ﹤0.01% | 3531 |
|
|
2017
Q1 | $13K | Buy |
54
+24
| +80% | +$5.39K | ﹤0.01% | 3716 |
|
|
2016
Q4 | $48K | Buy |
30
+25
| +500% | +$5.08K | ﹤0.01% | 2205 |
|
|
2016
Q3 | $9K | Hold |
5
| – | – | ﹤0.01% | 3701 |
|
|
2016
Q2 | $2K | Buy |
5
+2
| +67% | +$447 | ﹤0.01% | 4968 |
|
|
2016
Q1 | $2K | Buy |
+3
| New | +$576 | ﹤0.01% | 4763 |
|
|
2015
Q4 | – | Sell |
-4
| Closed | -$3K | – | 5891 |
|
|
2015
Q3 | $3K | Hold |
4
| – | – | ﹤0.01% | 4380 |
|
|
2015
Q2 | $2K | Sell |
4
-6
| -60% | -$1.03K | ﹤0.01% | 4312 |
|
|
2015
Q1 | $17K | Sell |
10
-7
| -41% | -$1.44K | ﹤0.01% | 2465 |
|
|
2014
Q4 | $29K | Buy |
+17
| New | +$3.63K | ﹤0.01% | 1775 |
|
Other funds holding NKTR
BI
TSC
VCM
PM
AC
Simplex Trading's NKTR Position: Q1 2026 in Review
Simplex Trading reduced its Nektar Therapeutics (NKTR) stake by 74% in Q1 2026, selling an estimated $923K and leaving 5,722 shares worth $412K. The position accounts for ﹤0.01% of the portfolio, ranked #3501.
Simplex Trading first reported a position in NKTR in Q4 2014 and has held it in 41 quarters since. The position peaked at $4.35M in Q3 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.
- Simplex Trading held 5,722 shares of Nektar Therapeutics worth $412K as of Q1 2026.
- Simplex Trading sold 16,214 Nektar Therapeutics shares in Q1 2026, an estimated $923K.
- Nektar Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #3501 holding.
- Simplex Trading first reported a position in Nektar Therapeutics in Q4 2014 and has held it in 41 quarters since.
- Simplex Trading's Nektar Therapeutics position peaked at $4.35M in Q3 2025.
- 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.
Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.